Article
Urology & Nephrology
Jack R. Andrews, Mohamed E. Ahmed, Vidit Sharma, Cameron Britton, Bradley Stish, Ryan Phillips, A. Tuba Kendi, Vidhu B. Joshi, Akshay Sood, Mathew K. Tollefson, Stephen A. Boorjian, R. Jeffery Karnes, Eugene D. Kwon
Summary: This study characterizes the outcomes of metastasis-directed therapy without concurrent androgen deprivation therapy in patients with solitary metastatic lesions in prostate cancer. The results demonstrate that this approach can delay the initiation of systemic therapy and call for further prospective studies in patients with solitary recurrent prostate cancer metastases.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Daniel J. Herr, David A. Elliott, Gillian Duchesne, Kristian D. Stensland, Megan E. V. Caram, Christina Chapman, Jennifer A. Burns, Brent K. Hollenbeck, Jordan B. Sparks, Chris Shin, Alexander Zaslavsky, Alexander Tsodikov, Ted A. Skolarus
Summary: This study aims to examine the 10-year clinical outcomes of patients with localized prostate cancer undergoing radiation therapy within a national healthcare system. The results showed improved survival rates for high-risk disease, providing important benchmarks for clinical decision-making.
Article
Urology & Nephrology
Kenneth J. Pienta, Michael A. Gorin, Steven P. Rowe, Peter R. Carroll, Frederic Pouliot, Stephan Probst, Lawrence Saperstein, Mark A. Preston, Ajjai S. Alva, Akash Patnaik, Jeremy C. Durack, Nancy Stambler, Tess Lin, Jessica Jensen, Vivien Wong, Barry A. Siegel, Michael J. Morris
Summary: The study aimed to evaluate the diagnostic performance of F-18-DCFPyL positron emission tomography/computerized tomography in detecting metastatic sites of prostate cancer. The results showed high specificity and positive predictive value, but moderate sensitivity.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Carlo A. Bravi, Giuseppe Rosiello, Giuseppe Fallara, Emily Vertosick, Amy Tin, Daniel Sjoberg, Marco Bianchi, Elio Mazzone, Alberto Martini, Paolo Dell'oglio, Armando Stabile, Giorgio Gandaglia, Nicola Fossati, Alberto Briganti, Francesco Montorsi, Andrew Vickers
Summary: The neutrophil-to-lymphocyte ratio does not have clinical utility for predicting adverse pathology and biochemical recurrence in localized prostate cancer patients undergoing radical prostatectomy. Further research should focus on its value for predicting regional lymph node metastasis.
MINERVA UROLOGY AND NEPHROLOGY
(2021)
Article
Urology & Nephrology
Charles J. Ryan, Xuehua Ke, Marie-Helene Lafeuille, Hela Romdhani, Frederic Kinkead, Patrick Lefebvre, Allison Petrilla, Zul Pulungan, Seung Kim, Denise M. D'Andrea, Peter Francis, Stephen J. Freedland
Summary: This study provides a contemporary assessment of the treatment patterns, health care resource utilization, and costs among metastatic castration-sensitive prostate cancer patients in the U.S. The study found limited use of newer therapies that improve survival in men with mCSPC in the U.S., and substantial increases in health care resource utilization and costs after onset of metastasis.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Daniel D. Joyce, Vidit Sharma, David H. Jiang, Holly K. Van Houten, Lindsey R. Sangaralingham, Bijan J. Borah, Eugene D. Kwon, David F. Penson, Stacie B. Dusetzina, Jon C. Tilburt, Stephen A. Boorjian
Summary: This study evaluated the patient-level factors associated with out-of-pocket costs for advanced prostate cancer treatment options. The findings showed that patients receiving novel hormonal therapy had significantly higher treatment-related out-of-pocket costs. Older age, Black race, lower comorbidity scores, and lower household income were associated with higher treatment-related out-of-pocket costs.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, Simon Chowdhury, Andrea J. Pereira de Santana Gomes, Byung Ha Chung, Mustafa Ozguroglu, Alvaro Juarez Soto, Axel S. Merseburger, Hirotsugu Uemura, Dingwei Ye, Robert Given, Ethan Basch, Branko Miladinovic, Angela Lopez-Gitlitz, Kim N. Chi
Summary: This study explored the impact of pain and fatigue on quality of life in patients with metastatic castration-sensitive prostate cancer. Patients receiving apalutamide plus ADT reported better pain outcomes, while there was no significant difference in fatigue between the treatment groups.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Daniel D. D. Joyce, Phillip J. J. Schulte, Eugene D. D. Kwon, Stacie B. B. Dusetzina, Kelvin A. A. Moses, Vidit Sharma, David F. F. Penson, Jon C. C. Tilburt, Stephen A. A. Boorjian
Summary: Through patient surveys, this study found that patients with metastatic prostate cancer and high financial toxicity were more likely to decrease spending on basic goods and leisure activities, as well as use savings to pay for their treatment. Understanding the impact of financial toxicity on patients' lives is crucial for decision-making and intervention strategies.
JOURNAL OF UROLOGY
(2023)
Review
Urology & Nephrology
N. Shore, L. Oliver, I. Shui, A. Gayle, O. Y. Wong, J. Kim, S. Payne, S. Amin, S. Ghate
Summary: This study characterized the global epidemiology of different types of metastatic prostate cancer and assessed the prevalence and prognostic impact of homologous recombination repair gene alterations in advanced disease setting. The results indicated that there is limited real-world evidence on the prevalence of prostate cancer and HRRm beyond mCRPC, with BRCA2 being one of the most common genes associated with HRRm in mCRPC.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Andrew J. Armstrong, Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, Arnulf Stenzl
Summary: The study found that treatment with enzalutamide plus androgen deprivation therapy provides significant improvements in men with bone and/or lymph node metastases but may be less effective in men with visceral patterns of spread.
JOURNAL OF UROLOGY
(2021)
Review
Urology & Nephrology
Takafumi Yanagisawa, Pawel Rajwa, Tatsushi Kawada, Keiichiro Mori, Wataru Fukuokaya, Patrik Petrov, Fahad Quhal, Ekaterina Laukhtina, Markus von Deimling, Alberto Bianchi, Muhammad Majdoub, Benjamin Pradere, Gero Kramer, Takahiro Kimura, Shahrokh F. F. Shariat
Summary: This study analyzed and compared the efficacy of combination systemic therapies in metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer with or without visceral metastasis. It was found that adding androgen receptor signaling inhibitor to standard of care improved overall survival in patients with visceral metastasis. In metastatic hormone-sensitive prostate cancer patients, darolutamide + docetaxel + androgen deprivation therapy had the highest likelihood of improved overall survival.
JOURNAL OF UROLOGY
(2023)
Review
Oncology
Tiuri E. Kroese, Hanneke W. M. Van Laarhoven, Magnus Nilsson, Florian Lordick, Matthias Guckenberger, Jelle P. Ruurda, Domenico D'Ugo, Karin Haustermans, Eric Van Cutsem, Richard Van Hillegersberg, Peter S. N. Van Rossum
Summary: Local treatment may improve overall survival in patients with esophagogastric cancer and oligometastatic disease (OMD). The current literature defines OMD as the presence of metastases limited to one organ with no more than three lesions and the presence of an extra-regional lymph node station. Local treatment appears to be associated with improved OS compared to systemic therapy alone.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Urology & Nephrology
Kazuhiro Matsumoto, Minami Omura, Toshikazu Takeda, Takeo Kosaka, Akinori Hashiguchi, Kimiharu Takamatsu, Yota Yasumizu, Nobuyuki Tanaka, Shinya Morita, Ryuichi Mizuno, Hiroshi Asanuma, Mototsugu Oya
Summary: The prognosis of discordant cases in prostate cancer is better determined by the secondary cancer lesion with the highest Grade Group instead of the largest lesion.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Michal Horny, K. Robin Yabroff, Christopher P. Filson, Zhiyuan Zheng, Donatus U. Ekwueme, Thomas B. Richards, David H. Howard
Summary: This study aimed to provide updated information on the cost to payers attributable to metastatic prostate cancer. By using commercial and Medicare supplemental data from 2009-2019, the authors calculated differences in spending between patients with metastatic prostate cancer and their matched controls. The findings showed a high cost burden attributable to metastatic prostate cancer, and these estimates can enhance the precision of value assessments of clinical and policy approaches to prostate cancer prevention, screening, and treatment.
Article
Oncology
Sebastien Thureau, Vincent Marchesi, Marie-Helene Vieillard, Lionel Perrier, Albert Lisbona, Marianne Leheurteur, Jean Tredaniel, Stephane Culine, Bernard Dubray, Naima Bonnet, Bernard Asselain, Julia Salleron, Jean-Christophe Faivre
Summary: SBRT combined with standard care treatment may improve progression-free survival in solid tumor patients with up to 3 bone-only metastases. A multicenter randomized phase III trial will recruit 196 patients to investigate the efficacy of this treatment approach.
Editorial Material
Urology & Nephrology
Akya K. Myrie, Richard S. Matulewicz
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Richard S. Matulewicz, Ramsankar Basak, Ibardo Zambrano, Bianca A. Dearing, Daniel Schatz, Omar El Shahawy, Scott Sherman, Marc A. Bjurlin
Summary: Among survivors of genitourinary cancers, those with a reported history of smoking-related cancers had a higher prevalence of current cigarette smoking and reported more frequent receipt of smoking cessation counseling, but did not attempt to quit smoking any more often.
JOURNAL OF UROLOGY
(2021)
Editorial Material
Andrology
Richard S. Matulewicz, Danil V. Makarov, Scott E. Sherman, Sarah A. Birken, Marc A. Bjurlin
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2021)
Article
Oncology
Marc A. Bjurlin, Ramsankar Basak, Ibardo Zambrano, Daniel Schatz, Omar El Shahawy, Scott Sherman, Richard S. Matulewicz
Summary: The study found that survivors of tobacco-related cancers have a significantly higher prevalence of cigarette smoking and e-cigarette use compared to survivors of non-tobacco related cancers. The prevalence of smoking among all survivors increased each subsequent year from the time of new cancer diagnosis, highlighting the need for long-term tobacco cessation support for newly diagnosed adults with cancer.
CANCER EPIDEMIOLOGY
(2022)
Review
Urology & Nephrology
Calvin Zhao, Marc A. Bjurlin, Timothy Roberts, Michael Rink, Shahrokh F. Shariat, Richard S. Matulewicz
Summary: This study found that there is a low smoking cessation rate among urological cancer patients after diagnosis, and there is a lack of support from urologists in helping patients quit smoking.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Richard S. Matulewicz, Jeffrey C. Bassett, Lorna Kwan, Scott E. Sherman, William J. McCarthy, Christopher S. Seigal, John L. Gore
Summary: A strategy that includes provider education and a customized clinical decision support tool can facilitate provider use of evidence-based practices for tobacco cessation in a urology clinic.
Review
Oncology
Christopher Svendsen, Andrew James, Richard S. Matulewicz, Elizabeth Moreton, Roman Sosnowski, Scott Sherman, Ilona Jaspers, Terry Gordon, Marc A. Bjurlin
Summary: This study aims to identify biomarkers of exposure associated with bladder cancer in heated tobacco product (HTP) users' urine. The findings showed that biomarkers of exposure to bladder carcinogens are present in the urine of HTP users, although at lower levels than combustible cigarette users. Further long-term study is needed to determine the bladder cancer risk of HTP use.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Richard S. Matulewicz, Kourosh Ravvaz, John A. Weissert, Sima Porten, Gary D. Steinberg
Summary: The study found no significant association between smoking status and recurrence in a cohort primarily consisting of high-risk recurrent NMIBC patients. The results suggest that smoking may not play a significant role in the recurrence of non-muscle invasive bladder cancer.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Article
Oncology
Giovanni E. Cacciamani, Richard S. Matulewicz, Raj Kumar, Jeremy Yuen-Chun Teoh, Andrea Mari, Benjamin Pradere, Juan Gomez Rivas, Andrea Necchi, Sumanta Kumar Pal, Maria J. Ribal, Shahrokh Shariat, Michael Rink
Summary: The association between tobacco use and urothelial cancer of the bladder is well known. Interventions for urologists and other professionals should be made to address this issue. Awareness of contemporary checkpoints for intervention may aid medical education in challenging tobacco epidemic settings.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2021)
Editorial Material
Urology & Nephrology
Jamie Michael, Richard S. Matulewicz, Marc A. Bjurlin
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Calvin C. Zhao, Marc A. Bjurlin, James S. Wysock, Samir S. Taneja, William C. Huang, David Fenyo, Richard S. Matulewicz
Summary: The purpose of this study was to improve the discharge planning process by creating a machine learning model that predicts the need for non-home hospital discharge. The model showed strong performance in identifying patients who required higher levels of care, outperforming commonly used clinical indices and prior work.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2022)
Article
Oncology
Sarah D. Hohl, Richard S. Matulewicz, Ramzi G. Salloum, Jamie S. Ostroff, Timothy B. Baker, Robert Schnoll, Graham Warren, Steven L. Bernstein, Mara Minion, Katie Lenhoff, Neely Dahl, Hee Soon Juon, Ursula Tsosie, Linda Fleisher, Heather D'Angelo, Alex T. Ramsey, Kimlin T. Ashing, Betsy Rolland, Margaret B. Nolan, Jennifer E. Bird, Claire V. T. Nguyen, Danielle Pauk, Robert T. Adsit, Hilary A. Tindle, Kimberly Shoenbill, Sophia Yeung, Cary A. Presant, Kara P. Wiseman, Kuang-Yi Wen, Lou-Anne Chichester, Li-Shiun Chen
Summary: The C3I program found that implementing comprehensive tobacco treatment programs and improving the staff-to-patient ratio can increase the reach of cessation treatment. Strengthening the tobacco treatment team and providing more resources can improve the effectiveness of smoking cessation.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Eli Rapoport, Marc A. Bjurlin, Helena Furberg, Timothy F. Donahue, Samir S. Taneja, Bernard H. Bochner, Jamie S. Ostroff, Richard S. Matulewicz
Summary: This study aimed to assess gaps in urologic oncology quality and evidence-based smoking cessation care after cystectomy, and found that the proportion of patients receiving smoking cessation pharmacotherapy was low and varied. Factors such as age, race, and patient comorbidity score were associated with the likelihood of receiving smoking cessation pharmacotherapy. The findings indicate inadequate urologic oncology care and missed opportunities for effective intervention in bladder cancer surgery patients.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
(2023)
Article
Urology & Nephrology
Richard S. Matulewicz, William Meeks, Rachel Mbassa, Raymond Fang, Ashley Pittman, Matthew Mossanen, Helena Furberg, Lou-Anne Chichester, Michelle Lui, Scott E. Sherman, Danil Makarov, Marc A. Bjurlin, Jamie S. Ostroff
Summary: This study aimed to assess urologists' perceptions and practices related to smoking and smoking cessation. The results of the survey showed that most urologists recognized the significant contribution of cigarette smoking to urologic disease, but there was a low level of agreement on the importance of tobacco use assessment and treatment in urology clinics. Furthermore, when advising patients who smoke, urologists tended to not provide additional counseling or medications and faced various barriers such as lack of time, patient unwillingness to quit, and discomfort in prescribing cessation medications.
Article
Urology & Nephrology
Sarah A. Birken, Richard Matulewicz, Ram Pathak, Cheyenne R. Wagi, Alexandra G. Peluso, Richa Bundy, Lauren Witek, Bridget Krol, Michael L. Parchman, Matthew Nielsen, Ajay Dharod
Summary: This study aimed to investigate the factors contributing to the continued use of low-value CT urogram after guideline revision. The study used a mixed-method design, utilizing electronic health record data and semi-structured interviews, to examine the determinants of low-value CT urogram at a single academic tertiary medical center in the southeastern United States. The findings suggest that provider awareness of the revised guidelines, clinical judgment, and external influences play a role in the use of low-value CT urogram.